Fate Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Fate Therapeutics

03/11/2022 21:03

* Fate Therapeutics Inc  FATE.OQ  reported a quarterly
adjusted
loss of 86 cents​​ per share for the quarter ended in September.
The mean expectation of twenty two analysts for the quarter was
for a loss of 89 cents per share.
    * Revenue rose 5.3% to $14.98 million from a year ago;
analysts
expected $15.63 million. 
    * Fate Therapeutics Inc's reported EPS for the quarter was a
loss
of 86 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.2%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Fate Therapeutics Inc shares had fallen by 10.6% this
quarter and lost 65.7% so far this year.
    * The company reported a quarterly loss of $83.56 million.
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $71.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 19 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 09:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.89          -0.86          Beat
 Jun. 30 2022      -0.83          -0.79          Beat
 Mar. 31 2022      -0.77          -0.68          Beat
 Dec. 31 2021      -0.67          -0.72          Missed